Traders Sell Johnson & Johnson (JNJ) on Strength (JNJ)

Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Wednesday. $186.17 million flowed into the stock on the tick-up and $300.65 million flowed out of the stock on the tick-down, for a money net flow of $114.48 million out of the stock. Of all equities tracked, Johnson & Johnson had the 0th highest net out-flow for the day. Johnson & Johnson traded up $2.75 for the day and closed at $136.65

Several equities analysts have weighed in on the company. J P Morgan Chase & Co increased their price objective on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday, August 16th. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $129.62 price objective for the company. in a report on Friday. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Wells Fargo & Company reissued a “market perform” rating and set a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Finally, UBS AG reissued a “buy” rating and set a $148.00 price objective (up from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. Five analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and an average target price of $135.98.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. During the same quarter in the prior year, the firm posted $1.74 EPS. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in JNJ. Harding Loevner LP purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in shares of Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. raised its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares in the last quarter. IHT Wealth Management LLC raised its position in shares of Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $124,000. 65.90% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Traders Sell Johnson & Johnson (JNJ) on Strength (JNJ)” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://stocknewstimes.com/2017/10/13/traders-sell-johnson-johnson-jnj-on-strength-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply